CLINICAL_TRIALS
trial_result
· 2017-09-26
Clinical Trial Update: Zostavax® at Minimum Release Specification Approaching Expiry (V211-044) [Phase 4]
Summary
Phase 4 trial update on Zostavax nearing expiry of minimum release specification; results posted after completion.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Herpes Zoster | Phase 4 | Status: COMPLETED | Results posted: 2017-09-26